Efficacy of Intersectional Short Pulse Stimulation for Terminating Seizures

NYU Langone Health

Overview

This is a study which seeks to develop a novel therapeutic approach, Intersectional Short Pulse (ISP) stimulation for seizure termination. The device embodiment of ISP is a scalp EEG recording system which also delivers spatially precise electrical stimulation in short pulses to the targeted brain region. The study team has already collected safety and tolerability data in human subjects, demonstrated ISP efficacy in terminating seizures in rodents, and have tested the efficacy of this device to modulate normal human brain activity. Now this study proposes to test the device's efficacy in stopping seizures in a within-subject randomized, sham-controlled study design.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Conditions

Seizures Focal Epilepsy

Interventions

SeizureStop DeviceDEVICE

Intersectional Short Pulse (ISP) Stimulation will be performed using SeizureStop Device. The ISP stimulation method proposed in this study is to increase the intensity of stimulation delivered to targeted brain regions, while minimizing the peripheral effects of stimulation. For sham stimulation, no settings will be modified.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Experiment 3: Epilepsy patients Inclusion criteria: * Adult patients (age 18-65). * Fluent in English. * Epilepsy patients with poorly controlled (\>=2 seizures per week). * Focal onset seizures. * Seizure onset zone in the mesial temporal or neocortical onset as determined by \>2 concordant criteria, without discordant criteria (semiology, MRI Brain, and EEG). * Able to give informed consent. Exclusion criteria: * Patients with skull defects. * Patients with implanted neurostimulator or other implanted cerebral hardware. * Patients with multifocal onset epilepsy. * Patients who are non-verbal or incapable of providing informed consent. * Current substance abuse. * Pregnancy. * Patients with non-MRI compatible implants (for Experiments 2 and 3).

Outcomes

Primary Outcomes

Mean duration of seizures detected

Time frame: up to Day 10

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.